Checkpoint Therapeutics, Inc. (Fri, May 03, 2024)

Hold candidate since May 03, 2024



StockInvest.us Gyneju st. 14, "ROCKIT" Vilnius, LT-01109 Lithuania



Trend:	Sell
MV Long:	Sell
MV Short:	Buy
Pivot:	Buy
Volume:	Buy
MACD:	Sell

Tech commentaries:

The Checkpoint Therapeutics, Inc. stock price gained 6.76% on the last trading day (Friday, 3rd May 2024), rising from \$1.48 to \$1.58. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 15.44% from a day low at \$1.47 to a day high of \$1.70. The price has risen in 6 of the last 10 days and is up by 8.22% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 289 thousand more shares were traded than the day before. In total, 613 thousand shares were bought and sold for approximately \$969.03 thousand.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -24.18% during the next 3 months and, with a 90% probability hold a price between \$1.03 and \$1.44 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

A buy signal was issued from a pivot bottom point on Tuesday, April 30, 2024, and so far it has risen 13.67%. Further rise is indicated until a new top pivot has been found. Checkpoint Therapeutics, Inc. has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation. Higher liquidity also reduces the general risk. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Checkpoint Therapeutics, Inc. stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at \$1.74. On a fall, the stock will find some support from the short-term average at \$1.45. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

On the downside, the stock finds support just below today's level from accumulated volume at \$1.46 and \$1.44. On the upside the stock meets some resistance from accumulated volume at \$1.85, \$1.90 and \$1.92.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved **\$0.227** between high and low, or **15.44%**. For the last week, the stock has had daily average volatility of 8.31%.

Checkpoint Therapeutics, Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. We have upgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Hold/Accumulate candidate.

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.